Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.55 |
| ▸ | SELP | P16109 | 2/20 | 0.52 |
| ▸ | SELL | P14151 | 1/20 | 0.52 |
| ▸ | MAG | P20916 | 8/20 | 0.52 |
| ▸ | SELE | P16581 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25588661 | 0.94 | SELP (0.55) | SIGLEC7SELPSELLMAGSELE | |
| SCHEMBL12136198 | 0.94 | SELP (0.55) | SIGLEC7SELPSELLMAGSELE | |
| SCHEMBL17988418 | 0.94 | SELP (0.55) | SIGLEC7SELPSELLMAGSELE | |
| SCHEMBL17973946 | 0.94 | SELP (0.55) | SIGLEC7SELPSELLMAGSELE | |
| SCHEMBL12136277 | 0.90 | SELP (0.55) | SIGLEC7SELPSELLMAGSELE | |
| SCHEMBL26491408 | 0.90 | MAG (0.52) | SIGLEC7SELPSELLMAGSELE | |
| SCHEMBL19489048 | 0.90 | SIGLEC7 (0.54) | SIGLEC7SELPSELLMAGSELE | |
| SCHEMBL769309 | 0.90 | SIGLEC7 (0.59) | SIGLEC7SELPSELLMAGSELE | |
| SCHEMBL18214012 | 0.89 | SIGLEC7 (0.53) | SIGLEC7SELPSELLMAGSELE | |
| SCHEMBL18011724 | 0.89 | SIGLEC7 (0.53) | SIGLEC7SELPSELLMAGSELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11672815-B2 | Composition for inhibiting immune cell proliferation comprising sialyllactose or derivative thereof and method thereof | Cupione Co., Ltd. (KR) | 2023-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11672815-B2 | Composition for inhibiting immune cell proliferation comprising sialyllactose or derivative thereof and method thereof | CCL11, NEU2, CCL2 | SIGLEC7 44/4885SELP 282/4885SELL 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.